SCHEMBL31444592

SCHEMBL31444592

FC(F)(F)Oc1ccccc1C1CCCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GRIN2B Q13224 2/20 0.43
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ OPRM1 P35372 1/20 0.39
▸ CHRM5 P08912 3/20 0.38
▸ CHRM3 P20309 3/20 0.38
▸ CHRM1 P11229 2/20 0.38
▸ CHRM2 P08172 2/20 0.38
▸ CHRM4 P08173 2/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ DDB1 Q16531 2/20 0.36
▸ CRBN Q96SW2 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22040130 1.00 TACR1 (0.46) TACR1MEN1KMT2AGRIN2BHCRTR1
SCHEMBL4741235 0.80 HTR2C (0.45) TACR1GRIN2BHCRTR1HCRTR2OPRM1
SCHEMBL29589447 0.79 MEN1 (0.65) TACR1MEN1KMT2AHCRTR2HTR2C
SCHEMBL469013 0.79 MEN1 (0.65) TACR1MEN1KMT2AHCRTR2HTR2C
SCHEMBL23323077 0.79 MEN1 (0.65) TACR1MEN1KMT2AHCRTR2HTR2C
SCHEMBL16796794 0.78 TACR1 (0.46) TACR1MEN1KMT2ACHRM5CHRM3
SCHEMBL31198369 0.78 TACR1 (0.46) TACR1MEN1KMT2ACHRM5CHRM3
SCHEMBL28907795 0.78 MEN1 (0.48) TACR1MEN1KMT2ACHRM5CHRM3
SCHEMBL11509481 0.76 HTR1A (0.58) TACR1MEN1KMT2ACHRM5CHRM3
SCHEMBL16455098 0.76 HTR2A (0.53) HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072451-A1 RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES VIVIDION THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
Send feedback